3 results
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections2. To examine the safety of treatment3. To examine treatment effects on immunological parameters4. To develop and validate an immunological…
Primary: To evaluate the efficacy of repeated subcutaneous (SC) administrations of lanadelumab in preventing angioedema attacks in adolescents (12 to <18 years of age) and adults with non-histaminergic angioedema with normal C1-INH.Secondary…